Clinical Trial Update: A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-daily versus twice-daily dosing of eliglustat tartrate in Gaucher disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• Eliglustat Tartrate (Eliglustat tartrate)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Gaucher Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-12-02